drugset / Trial / NCT01090050

Treximet in the Treatment of Chronic Migraine

NCT01090050

Phase 4 Completed 56 enrolled Cady, Roger, M.D. GlaxoSmithKline · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being conducted to evaluate the hypothesis that use of Treximet in patients with chronic migraine, when used on a short term daily basis and as rescue for break through attacks, will reduce migraine frequency and impact.

Timeline

Start
2010-09
Primary completion
2012-06
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 500 mg Oral
Comparator Sumatriptan Unknown 85 mg Oral

Indications